Bioservo Technologies AB Interim Report January – March 2021
First quarter in figures · Net sales of SEK 1.5 M (3.0) · EBITDA of SEK -7.8 M (-6.6) · EBIT of SEK -9.0 M (-7.5) · Earnings for the period amounted to SEK -9.0 M (-7.5) · Earnings per share before and after dilution amounted to SEK -0.57 (-0.53) · Cash flow from operating activities for the period amounted to SEK -7.7 M (-6.2) · On 31 March, cash and cash equivalents were SEK 44.7 M (50.3) Significant events during the period · Bioservo obtained financing of SEK 5 million within the Horizon 2020 framework to develop the next generation of rehabilitative and